Sharp Therapeutics Announces Filing of Amended and Restated Management Information Circular and New Annual Meeting Date

Executive Summary

• Sharp Therapeutics Corp. has postponed its annual meeting of shareholders from June 30, 2026, to July 21, 2026.
• The company filed an amended and restated notice of meeting and management information circular to include the re-approval of the company's stock option plan, which was omitted from the original circular.
• Shareholders are instructed to disregard previously issued proxy forms and voting instructions; new forms and instructions will be provided with the amended documents.

Key Details

• Meeting Date Change: The annual meeting is now scheduled for July 21, 2026, at 10:00 a.m. (Toronto time), postponed from the original date of June 30, 2026.
• Amended Filings: The company filed an Amended and Restated Notice of Meeting (NOM) and an Amended and Restated Management Information Circular.
• Stock Option Plan Re-approval: The primary business item added to the meeting agenda is the re-approval of the Company's Stock Option Plan. This resolution was not included in the original circular dated May 27, 2026.
• Proxy Instructions:
  • Previous proxy forms and voting instructions are no longer valid.
  • Shareholders must submit new voting instructions using the new forms provided with the Amended and Restated Circular.
  • Proxies must be received by 10:00 a.m. (Toronto time) on July 17, 2026, or 48 hours prior to any adjourned or postponed meeting reconvening.
• Document Availability: Copies of the Amended and Restated NOM, Circular, and new proxy forms are available under the Company's profile on SEDAR+ at www.sedarplus.ca.